Table 1.
Patients’ demographic and clinical characteristics.
| Overall | UST | Anti-TNF | p-Value | |
|---|---|---|---|---|
| Patient number, N (%) | 59 | 28 (47.5) | 31 (52.5) | 0.7 |
| Demographics | ||||
| Mean (SD) age, years | 52 (19) | 58 (17.5) | 46 (19) | 0.9 |
| Gender [male], n(%) | 25 (42.4) | 12 (42.8) | 13 (41.9) | 0.9 |
| Gender [female], n(%) | 34 (57.6) | 16 (57.1) | 18 (58) | 0.9 |
| Smoking status | ||||
| Current, n (%) | 9 (15.2) | 5 (17.8) | 4 (12.9) | 0.6 |
| Former, n (%) | 13 (22) | 8 (28.5) | 5 (16.1) | 0.3 |
| Never smoked, n (%) | 37 (62.8) | 15 (53.5) | 22 (70.9) | 0.5 |
| Clinical characteristics | ||||
| Disease duration, years (IQR) | 35 (23–56.5) | 43 (25–60) | 36 (21–48) | 0.4 |
| Disease location | ||||
| Ileal | 19 (32.4) | 11 (39.2) | 8 (25.8) | 0.4 |
| Colonic | 18 (30.5) | 9 (32.1) | 9 (29) | 0.8 |
| Ileocolonic | 21 (35.5) | 7 (25) | 14 (45.1) | 0.2 |
| Upper-GI | 1 (1.6) | 1 (3.5) | 0 (0) | 0.4 |
| Behavior | ||||
| Non-stricturing, non-penetrating | 39 (66.2) | 20 (71.4) | 19 (61.2) | 0.7 |
| Stricturing | 16 (27.1) | 7 (25) | 9 (29) | 0.7 |
| Penetrating | 4 (6.7) | 1 (3.5) | 3 (9.6) | 0.3 |
| Perianal disease | 5 (8.4) | 3 (10.7) | 2 (6.4) | 0.5 |
| History of surgery | 17 (28.8) | 8 (28.5) | 9 (29) | 0.9 |
| Mean vedolizumab therapy duration, months (IQR) | 12 (5–17) | 14.3 (6–18.7) | 10 (4–14) | 0.1 |
| Disease activity at treatment onset | ||||
| HBI median, (IQR) | 8 (6–9) | 9 (7–10.7) | 7 (6–9) | 0.6 |
| Elevated CRP, n (%) | 36 (66.6) | 16 (59.2) | 20 (74) | 0.7 |
| Elevated FCP, n (%) | 26 (68.4) | 12 (66.5) | 14 (70) | 0.9 |
| Concomitant corticosteroid | 23 (38.9) | 13 (46.4) | 10 (32.2) | 0.6 |
| Concomitant immunomodulators | 6 (10.1) | 1 (3.5) | 5 (16.1) | 0.1 |
Abbreviations: n, number; UST, ustekinumab; anti-TNF, anti-tumor necrosis factor; IQR, interquartile range; Upper-GI, upper gastrointestinal; HBI, Harvey–Bradshaw Index, CRP, C-reactive protein; FCP, Fecal Calprotectin; SD, Standard deviation.